A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
Amgen has developed a collection of online resources available to help you learn more about areas of interest.
Do you want to link to this External Site and leave Amgen.com?
YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.
Read our submitted letters to editors and responses to Amgen news.
Sep. 12, 2016Amgen Response to ICER’s Call for Comments on its Value Assessment Framework
Sep. 9, 2016Amgen Statement on the Clinical and Economic Value of BLINCYTO® (Blinatumomab) in Treating Adults With Relapsed or Refractory Philadelphia Chromosome Negative B-Cell Precursor Acute Lymphoblastic Leukemia